We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oversensitive COVID-19 Tests Detecting Dead Coronavirus Cells, Driving False Positives and Reinfections

By LabMedica International staff writers
Posted on 07 Sep 2020
Print article
Illustration
Illustration
A study by the Oxford University’s Centre for Evidence-Based Medicine (Oxford, England) suggests that the current COVID-19 diagnostic tests could be too sensitive and may be detecting dead coronavirus cells, leading to overestimated infections.

According to the researchers, the tests used to diagnose COVID-19 are so sensitive that they may be indicating people are infected with SARS-CoV-2 even when they had the virus 70 days ago. Prof Carl Heneghan, director of the Centre for Evidence-Based Medicine, believes that eight days after contracting COVID-19, the chances of an infected person passing on the virus to others become zero if there are no symptoms. However, fragments of the coronavirus can still remain in the body for several weeks afterwards.

Polymerase chain reaction (PCR) tests currently used to detect SARS-CoV-2 have technical limitations as they cannot distinguish whether the virus in the patient is alive or dead. The researchers analyzed 25 studies on PCR tests and found that such tests can suggest people are infected even after their bodies’ immune system has already fought off the coronavirus because these tests only provide a ‘yes’ or ‘no’ as to whether the virus material is in the body. This means such people would test positive even though the coronavirus in their bodies may be harmless and non-infectious.

"After about day eight, you can still find the RNA fragments," Prof Heneghan told BBC Radio 4's Today program. "Some studies have reported up to 70 days that you intermittently shed. You can understand the importance of this, because what you want to do is find those with active infection and not those with the RNA fragments."

“Evidence is mounting that a good proportion of ‘new’ mild cases and people re-testing positive after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with,” added Prof Heneghan.

Earlier, a team of South Korean researchers had revealed that reports of recovered coronavirus patients testing positive for SARS-CoV-2 infection a second time round were most likely due to dead-virus fragments. They found that 260 people who had recovered and were declared virus-free tested positive again in South Korea but had little or no contagiousness at all. This meant that they were incapable of transmitting the virus to others, based on virus culture cells that all failed to find live viruses in the recovered patients.

“PCR testing that amplifies genetics of the virus is used in Korea to test COVID-19, and relapse cases are due to technical limits of the PCR testing. The respiratory epithelial cell has a half-life of up to three months, and RNA virus in the cell can be detected with PCR testing one to two months after the elimination of the cell,” said Oh Myoung-don, who spearheads the central clinical committee for emerging disease control in South Korea.

Related Links:
Oxford University’s Centre for Evidence-Based Medicine

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.